AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38017500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed collagen (10 g) and vitamin C (40 mg) supplementation for 24 weeks combined with progressive tendon loading exercises (PTLE)
Number of subjects: 76
Study 38017500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 g maltodextrin) combined with progressive tendon loading exercises (PTLE)
Number of subjects: 76
Study 38017522 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-Based Care (MBC)
Number of subjects: 0
Study 38017522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic implementation methods (including rapid evidence synthesis, rapid ethnography, design kits, barrier prioritization, causal pathway diagramming)
Number of subjects: 0
Study 38017522 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit for design kit methods co-designed with youth and communities
Number of subjects: 0
Study 38017564 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/Singapore/INFIMH-16-0019/2016(H3N2)-like virus vaccine
Number of subjects: 24
Study 38017564 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 24
Study 38017574 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSeT intervention (online psychoeducational program and video therapy sessions)
Number of subjects: 106
Study 38017574 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 106
Study 38017574 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSeT intervention
Number of subjects: 106
Study 38017663 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel as add-on therapy
Number of subjects: 100
Study 38017663 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel as substitution therapy
Number of subjects: 100
Study 38017663 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 100
Study 38017663 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (overall)
Number of subjects: 100
Study 38018158 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily egg consumption for six months
Number of subjects: 446
Study 38018158 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 446
Study 38018175 — intervention group
Group type: EXPERIMENTAL
Intervention: HdxSim
Number of subjects: 0
Study 38018175 — intervention group
Group type: COMPARATOR
Intervention: MWPharm-DOS
Number of subjects: 0
Study 38018460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab (anti-PD-1 antibody) added to radiation therapy
Number of subjects: 0
Study 38018707 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance-dependent tissue sealer (IDTS) tonsillectomy
Number of subjects: 1250
Study 38018707 — intervention group
Group type: COMPARATOR
Intervention: Cold steel tonsillectomy
Number of subjects: 1250
Study 38018707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1250
Study 38018702 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (equivalent to 20 mg/day of simvastatin)
Number of subjects: 50725
Study 38018702 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 50725
Study 38018833 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NIHSS score (cut point ≥10)
Number of subjects: 2829
Study 38018833 — intervention group
Group type: COMPARATOR
Intervention: Baseline Glasgow Coma Scale score
Number of subjects: 2829
Study 38018833 — intervention group
Group type: COMPARATOR
Intervention: ICH score
Number of subjects: 2829
Study 38018833 — intervention group
Group type: COMPARATOR
Intervention: max-ICH score
Number of subjects: 2829
Study 38018833 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NIHSS score (cut point 10)
Number of subjects: 2829
Study 38018833 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NIHSS score (cut point 12)
Number of subjects: 2829
Study 38018840 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided treatment decision
Number of subjects: 1682
Study 38018840 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided treatment decision
Number of subjects: 1682
Study 38018841 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 192
Study 38018841 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 192
Study 38019014 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline RUNX1 variants
Number of subjects: 51
Study 38019014 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic mutations in CHIP or AML driver genes
Number of subjects: 51
Study 38019014 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring changes in somatic mutations
Number of subjects: 51
Study 38019088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA, RBL)
Number of subjects: 0
Study 38019088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38019116 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant 30 mg once daily
Number of subjects: 0
Study 38019116 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant 90 mg once daily
Number of subjects: 0
Study 38019116 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant 100 mg combined with palbociclib 125 mg
Number of subjects: 0
Study 38019116 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant 10, 30, 90, or 250 mg once daily (dose-escalation stage)
Number of subjects: 0
Study 38019116 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant 30, 100, and 250 mg once daily (dose-expansion stage)
Number of subjects: 0
Study 38019287 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy sensory profile (HSP)
Number of subjects: 76
Study 38019287 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal hyperalgesia (TH)
Number of subjects: 76
Study 38019287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical hyperalgesia (MH)
Number of subjects: 76
Study 38019287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory loss (SL)
Number of subjects: 76
Study 38019287 — intervention group
Group type: COMPARATOR
Intervention: Comparison of phenotypes
Number of subjects: 76
Study 38019355 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1358894 (oral, single ascending dose, 3-50 mg in fasted state; 50-200 mg in fed state)
Number of subjects: 0
Study 38019355 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1358894 (oral, multiple ascending doses, 10-200 mg)
Number of subjects: 0
Study 38019356 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1358894 100 mg
Number of subjects: 20
Study 38019356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 38019444 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic oral cyclophosphamide and methotrexate (CM) combined with bevacizumab (Arm A)
Number of subjects: 55
Study 38019444 — intervention group
Group type: COMPARATOR
Intervention: Metronomic oral cyclophosphamide and methotrexate (CM) alone (Arm B)
Number of subjects: 55
Study 38019467 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led, telehealth-delivered cognitive behavioral therapy (CBT) program
Number of subjects: 87
Study 38019467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study 38019512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided revascularization
Number of subjects: 1639
Study 38019571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)
Number of subjects: 74
Study 38019571 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching condition (2 telephone coaching sessions)
Number of subjects: 74
Study 38019571 — intervention group
Group type: COMPARATOR
Intervention: No-coaching condition (no subsequent coaching)
Number of subjects: 74
Study 38019571 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP-YA intervention
Number of subjects: 74
Study 38019593 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Mindfulness-Based Exposure Therapy
Number of subjects: 0
Study 38019656 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccines (third doses)
Number of subjects: 78
Study 38019656 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 78
Study 38019657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir rectal douche 220 mg iso-osmolar product A
Number of subjects: 21
Study 38019657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir rectal douche 660 mg iso-osmolar product B
Number of subjects: 21
Study 38019657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir rectal douche 660 mg hypo-osmolar product C
Number of subjects: 21
Study 38019657 — intervention group
Group type: EXPERIMENTAL
Intervention: All three tenofovir douches
Number of subjects: 21
Study 38019901 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg with concomitant immunomodulator (IM)
Number of subjects: 0
Study 38019901 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 0
Study 38019956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) injection of 2 × 106 to 16 × 106 colony-forming units
Number of subjects: 92
Study 38019956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) injection
Number of subjects: 92
Study 38019968 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative airway strategy of intubation withholding
Number of subjects: 225
Study 38019968 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (intubation)
Number of subjects: 225
Study 38020057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 39357
Study 38020057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 39357
Study 38020057 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 39357
Study 38020116 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA)
Number of subjects: 124
Study 38020116 — intervention group
Group type: COMPARATOR
Intervention: Opioid-sparing anesthesia (OSA)
Number of subjects: 124
Study 38020175 — intervention group
Group type: EXPERIMENTAL
Intervention: GA + EA (General Anesthesia + Epidural Anesthesia)
Number of subjects: 60
Study 38020175 — intervention group
Group type: COMPARATOR
Intervention: GA alone (General Anesthesia only)
Number of subjects: 60
Study 38020201 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 16
Study 38020201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 16
Study 38020201 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (metabolic controls)
Number of subjects: 16
Study 38020288 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotralstat (150 mg daily)
Number of subjects: 39
Study 38020522 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment for overactive bladder
Number of subjects: 1504
Study 38020587 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Scan
Number of subjects: 147
Study 38020626 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF-based post-stroke rehabilitation program (ICF-PSRP)
Number of subjects: 52
Study 38021090 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT with optical skin surface motion monitoring and breath-hold technique
Number of subjects: 10
Study 38021251 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination-focused cognitive behavioral therapy (RF-CBT)
Number of subjects: 76
Study 38021251 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 76
Study 38021297 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnion collagen matrix wrap and bone marrow aspirate concentrate (BMAC) injection during graft preparation.
Number of subjects: 40
Study 38021297 — intervention group
Group type: COMPARATOR
Intervention: Standard ACLR (control group).
Number of subjects: 40
Study 38021373 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive-day group (daily 100 mg iron for 90 d, followed by daily placebo for another 90 d)
Number of subjects: 150
Study 38021373 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day group (same daily dose of iron and placebo on alternate days for 180 d)
Number of subjects: 150
Study 38022532 — intervention group
Group type: EXPERIMENTAL
Intervention: E7777 + anti-PD-1
Number of subjects: 100
Study 38022532 — intervention group
Group type: COMPARATOR
Intervention: E7777
Number of subjects: 100
Study 38022532 — intervention group
Group type: COMPARATOR
Intervention: anti-PD-1
Number of subjects: 100
Study 38022553 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX combined with anlotinib and penpulimab for 6-8 cycles, maintained with anlotinib and penpulimab for up to 1 year
Number of subjects: 300
Study 38022553 — intervention group
Group type: COMPARATOR
Intervention: XELOX alone for 6-8 cycles
Number of subjects: 300
Study 38022553 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA positive patients
Number of subjects: 300
Study 38022553 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA negative patients
Number of subjects: 300
Study 38022553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 300
Study 38022664 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK-SOX (autologous CIK cells combined with S-1+oxaliplatin)
Number of subjects: 59
Study 38022664 — intervention group
Group type: COMPARATOR
Intervention: SOX (S-1+oxaliplatin)
Number of subjects: 59
Study 38022757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 30
Study 38022757 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training
Number of subjects: 30
Study 38022757 — intervention group
Group type: COMPARATOR
Intervention: Control group (females without MS)
Number of subjects: 30
Study 38022953 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT-Silver
Number of subjects: 0
Study 38022953 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 0
Study 38023148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib + Lenalidomide + Dexamethasone (VRD)
Number of subjects: 0
Study 38023148 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib + Thalidomide + Dexamethasone (VTD)
Number of subjects: 0
Study 38023544 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (2 doses at months 0 and 1)
Number of subjects: 1149
Study 38023544 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (receipt of COVID-19 vaccine)
Number of subjects: 1149
Study 38023545 — intervention group
Group type: EXPERIMENTAL
Intervention: Better WASH households (defined by safe source of water for daily use, safe source of drinking water, private/shared flush toilet use, and always handwashing with soap after defecation)
Number of subjects: 55086
Study 38023545 — intervention group
Group type: COMPARATOR
Intervention: Control population (not specified in detail)
Number of subjects: 55086
Study 38023553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG; 50 mg once per day) plus Darunavir boosted with cobicistat (DRV/c; 800/150 mg once per day)
Number of subjects: 89
Study 38023553 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) regimen
Number of subjects: 89
Study 38023556 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral treatments for HCV
Number of subjects: 498
Study 38023564 — intervention group
Group type: EXPERIMENTAL
Intervention: Third SARS-CoV-2 vaccine (mRNA-1273 or BNT162b2)
Number of subjects: 580
Study 38023564 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (Moderna)
Number of subjects: 580
Study 38023564 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (Pfizer-BioNTech)
Number of subjects: 580
Study 38023564 — intervention group
Group type: EXPERIMENTAL
Intervention: Third vaccination in solid organ transplant recipients
Number of subjects: 580
Study 38023564 — intervention group
Group type: COMPARATOR
Intervention: Basic immunization (first and second vaccines)
Number of subjects: 580
Study 38023564 — intervention group
Group type: EXPERIMENTAL
Intervention: People living with HIV
Number of subjects: 580
Study 38023964 — intervention group
Group type: EXPERIMENTAL
Intervention: prevANS intervention (self-guided, online, via web or smartphone app)
Number of subjects: 2000
Study 38023967 — intervention group
Group type: EXPERIMENTAL
Intervention: iRTP (internet-based recovery training program)
Number of subjects: 69
Study 38023967 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 69
Study 38024244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib (20 mg) in combination with radiation and temozolomide
Number of subjects: 137
Study 38024244 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with radiation and temozolomide
Number of subjects: 137
Study 38024477 — intervention group
Group type: EXPERIMENTAL
Intervention: BendaEAM
Number of subjects: 108
Study 38025217 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced acute kidney injury (DI-AKI) cases
Number of subjects: 314
Study 38025217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxic drugs (e.g., vancomycin, NSAIDs, piperacillin/tazobactam)
Number of subjects: 314
Study 38025217 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics and predictive variables of DI-AKI
Number of subjects: 314
Study 38025217 — intervention group
Group type: EXPERIMENTAL
Intervention: Model performance
Number of subjects: 314
Study 38025217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater reliability (IRR) for DI-AKI adjudication
Number of subjects: 314
Study 38025406 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week exercise intervention
Number of subjects: 100
Study 38025406 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation service for enrolled participants
Number of subjects: 100
Study 38025416 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (NS)
Number of subjects: 0
Study 38025416 — intervention group
Group type: COMPARATOR
Intervention: Real-world polypharmacy treatment strategies
Number of subjects: 0
Study 38025433 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (NS)
Number of subjects: 0
Study 38025433 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (RWT)
Number of subjects: 0
Study 38025437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS)
Number of subjects: 28
Study 38025437 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta-burst stimulation (cTBS)
Number of subjects: 28
Study 38025437 — intervention group
Group type: COMPARATOR
Intervention: Sham theta-burst stimulation
Number of subjects: 28
Study 38025483 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Motional Training® (ET)
Number of subjects: 50
Study 38025483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ET)
Number of subjects: 50
Study 38025545 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) measurements at the site above the central part of the placenta
Number of subjects: 34
Study 38025545 — intervention group
Group type: COMPARATOR
Intervention: Control measurements outside of the placenta on the lower abdomen
Number of subjects: 34
Study 38025650 — intervention group
Group type: EXPERIMENTAL
Intervention: AF induction by burst pacing
Number of subjects: 42
Study 38025650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AF induction)
Number of subjects: 42
Study 38025806 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy for stage IIIA (30.2%) and stage IIIB (37.0%) patients
Number of subjects: 1838
Study 38025806 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (26.3% overall; 37.0% for stage IIIA and 11.1% for stage IIIB)
Number of subjects: 1838
Study 38025971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal lactoferrin trajectory (high/moderate-rapid decrease)
Number of subjects: 0
Study 38025971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal lactoferrin trajectory (moderate-slow decrease, high-slow decrease, high-stable)
Number of subjects: 0
Study 38026297 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led BASICS intervention
Number of subjects: 308
Study 38026295 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt reduction program
Number of subjects: 311
Study 38026295 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle general program
Number of subjects: 311
Study 38026375 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive warming
Number of subjects: 309
Study 38026375 — intervention group
Group type: COMPARATOR
Intervention: Routine warming
Number of subjects: 309
Study 38026401 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaranteed income ($500/month) during the first 12-months of follow-up (Phase I)
Number of subjects: 300
Study 38026401 — intervention group
Group type: COMPARATOR
Intervention: Waitlist arm participants (Control)
Number of subjects: 300
Study 38026477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic relaxing incision added to crural repair
Number of subjects: 0
Study 38026477 — intervention group
Group type: COMPARATOR
Intervention: Crural repair alone (Control)
Number of subjects: 0
Study 38026571 — intervention group
Group type: EXPERIMENTAL
Intervention: Openfit (automated identification)
Number of subjects: 24
Study 38026571 — intervention group
Group type: EXPERIMENTAL
Intervention: Openfit (semiautomated identification)
Number of subjects: 24
Study 38026571 — intervention group
Group type: EXPERIMENTAL
Intervention: Openfit (automated energy estimates)
Number of subjects: 24
Study 38026571 — intervention group
Group type: EXPERIMENTAL
Intervention: Openfit (semiautomated energy estimates)
Number of subjects: 24
Study 38026571 — intervention group
Group type: EXPERIMENTAL
Intervention: User Satisfaction Survey (USS)
Number of subjects: 24
Study 38026571 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Systems Usability Questionnaire (CSUQ)
Number of subjects: 24
Study 38026755 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-point Severity Scale of ARIA-E (SSAE-3)
Number of subjects: 75
Study 38026755 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point Severity Scale of ARIA-E (SSAE-5)
Number of subjects: 75